Therefore, it is imperative and time-critical to delve into the underlying mechanisms of BCR::ABL1-independent drug resistance in CML patients, which will enable the development of innovate and effective therapeutic strategies to benefit CML patients. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.